Abstracts Archive - Page 1712 of 2425 - ACR Meeting Abstracts

Abstract Number: 337 • 2015 ACR/ARHP Annual Meeting
Construct Validity of the Doyle Index in the Outcome Domain of Joint Activity in Hand Osteoarthritis Patients
W. Damman¹, R. Liu¹, M.C. Kortekaas^1,2, F.R. Rosendaal³, D. van der Heijde⁴ and M. Kloppenburg¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Flevoziekenhuis, Almere-Stad, Netherlands, ³Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) working group on hand osteoarthritis (OA) has endorsed a preliminary set of core domains for outcome measures in…
Abstract Number: 338 • 2015 ACR/ARHP Annual Meeting
Smoking and Alcohol Use Are Associated with Structural and Inflammatory Hand Osteoarthritis Features in a Population Based Study
Karin Magnusson¹, Alexander Mathiessen², Hilde Berner Hammer², Bård Natvig³, Kåre Birger Hagen¹, Nina Østerås¹ and Ida K. Haugen⁴, ¹Department of Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³General Practice, Oslo University, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Smoking has been shown to have a potential protective effect on radiographic knee osteoarthritis (OA), possibly mediated through lower body weight in smokers. A…
Abstract Number: 339 • 2015 ACR/ARHP Annual Meeting
More Inflammatory Signs on Ultrasound, Severe Pain and Stiffness Are Associated with Erosive Than Non-Erosive Hand Osteoarthritis
Olga Sleglova¹, Olga Ruzickova², Karel Pavelka¹ and Ladislav Senolt², ¹Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Hand osteoarthritis (HOA) causes considerable pain and disability. Radiographic HOA features show only a modest association with symptoms in HOA. Ultrasound is an easy…
Abstract Number: 340 • 2015 ACR/ARHP Annual Meeting
Radiographic Assessment of Hand Osteoarthritis – the Role of Oblique View Images
Kevin Staats¹, Ilse-Gerlinde Sunk¹, Claudia Schueller-Weidekamm², Gabriela Supp³, Birgit Niederreiter⁴, Tanja A. Stamm⁵, Josef S. Smolen⁶ and Klaus Bobacz¹, ¹Medical University of Vienna, Vienna, Austria, ²Department of Radiology, Medical University of Vienna, Vienna, Austria, ³Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁵Internal Medicine III, Vienna Medical University, Vienna, Austria, ⁶Dept of Medicine 3, Division of Rheumatology, Medical Univ Vienna, Vienna, Austria
Background/Purpose: To evaluate the role of oblique view images in the radiographic assessment of hand osteoarthritis (HOA).Methods: 159 patients of our HOA cohort were included.…
Abstract Number: 341 • 2015 ACR/ARHP Annual Meeting
Construct Validity of Four Hand Mobility Measures in Hand Osteoarthritis (HOA)
Féline Kroon¹, Jessica Bijsterbosch¹, Ingrid Meulenbelt², Frits R. Rosendaal³, Désirée van der Heijde¹ and Margreet Kloppenburg^1,3, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Molecular Epidemiology, Leiden University Medical Center, Leiden, Netherlands, ³Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The OMERACT HOA working group recently proposed ‘hand mobility' as an outcome measure in HOA trials, although no disease specific instruments are available yet.…
Abstract Number: 342 • 2015 ACR/ARHP Annual Meeting
The Effect of Erosive Status on Systemic Inflammatory Biomarkers in Hand Osteoarthritis
Alexander Mathiessen¹, Nina Østerås², Tore K. Kvien³, Hilde Berner Hammer⁴ and Ida K. Haugen⁵, ¹Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology,, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵P.O. Box 23, Diakonhjemmet Hospital, Vinderen, Norway
Background/Purpose : It is debated whether erosive hand osteoarthritis (OA) is a separate inflammatory subset of hand OA, or just a severe form of the same…
Abstract Number: 343 • 2015 ACR/ARHP Annual Meeting
Efficacy of Odanacatib in Postmenopausal Women with Osteoporosis: Subgroup Analyses of Data from the Phase 3 Long-Term Odanacatib Fracture Trial
Kenneth G. Saag¹, Peter Alexandersen², Claude-Laurent Benhamou³, Nigel Gilchrist⁴, Johan Halse⁵, E. Michael Lewiecki⁶, Kurt Lippuner⁷, Michael McClung⁸, Masataka Shiraki⁹, Carolyn A. DaSilva¹⁰, Nadia Verbruggen¹¹, Boyd B. Scott¹⁰ and Antonio Lombardi¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Center for Clinical and Basic Research, Vejle, Denmark, Ballerup, Denmark, ³Hôpital d’Orléans-la-Source, Orléans, France, Orleans, France, ⁴The Princess Margaret Hospital, Christchurch, New Zealand, Christchurch, New Zealand, ⁵Osteoporoseklinikken, Oslo, Norway, Oslo, Norway, ⁶New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA, Albuquerque, NM, ⁷Bern University Hospital, Bern, Switzerland, Bern, Switzerland, ⁸Oregon Osteoporosis Center, Portland, Oregon, USA, Portland, OR, ⁹Research Institute and Practice for Involutional Diseases, Nagano, Japan, Nagano, Japan, ¹⁰Merck & Co., Inc, Kenilworth, NJ, USA, Kenilworth, NJ, ¹¹MSD Europe Inc., Brussels, Belgium, Brussels, Belgium
Background/Purpose: Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term Odanacatib Fracture…
Abstract Number: 344 • 2015 ACR/ARHP Annual Meeting
Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis
H Ishibashi¹, DB Crittenden², A Miyauchi³, C Libanati⁴, J Maddox², L Chen² and A Grauer², ¹Ina Hospital, Saitama, Japan, ²Amgen Inc., Thousand Oaks, CA, ³Miyauchi Medical Center, Osaka, Japan, ⁴UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab is a sclerostin inhibitor that rapidly increases bone mineral density (BMD) through a dual effect on bone, causing increased bone formation and decreased…
Abstract Number: 345 • 2015 ACR/ARHP Annual Meeting
Relationship Between Total Hip BMD T-Score and Incidence of Nonvertebral Fracture with up to 8 Years of Denosumab Treatment
S Ferrari¹, C Libanati², CJF Lin², S Adami³, JP Brown⁴, F Cosman⁵, E Czerwinski⁶, LH de Gregório⁷, J Malouf⁸, J-Y Reginster⁹, NS Daizadeh², A Wang², RB Wagman² and EM Lewiecki¹⁰, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of Verona, Verona, Italy, ⁴Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ⁵Helen Hayes Hospital, West Haverstraw, NY, ⁶Krakow Medical Center, Krakow, Poland, ⁷CCBR, Rio de Janeiro, Brazil, ⁸Universitat Autònoma de Barcelona, Barcelona, Spain, ⁹University of Liège, Liège, Belgium, ¹⁰New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Background/Purpose: The relationship between BMD T-score and fracture risk has not been established in patients on therapy. We previously reported that denosumab (DMAb) treatment over…
Abstract Number: 346 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Osteoprotegerin Are Independently Associated with Low Hip Bone Mineral Density and Increased Fractures in Axial Spondyloarthritis
Sizheng Zhao^1,2, Barbara Hauser³, Micaela Visconti³, Philip L. Riches³, Stuart H. Ralston³ and Nicola Goodson^1,2, ¹Musculoskeletal Biology I, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ²Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom, ³Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom
Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis. However the underlying causes are incompletely understood. Osteoprotegerin (OPG) is a bone protective protein that acts as…
Abstract Number: 347 • 2015 ACR/ARHP Annual Meeting
Safety Observations with 3 Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab during the Pivotal 3-Year Trial and Subjects Who Crossed over to Denosumab during the Extension
NB Watts¹, JP Brown², S Papapoulos³, EM Lewiecki⁴, DL Kendler⁵, P Dakin⁶, RB Wagman⁶, A Wang⁶, NS Daizadeh⁶, S Smith⁶ and HG Bone⁷, ¹Mercy Health, Cincinnati, OH, ²Laval University and CHU de Québec (CHUL) Research Centre, Québec City, QC, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Michigan Bone and Mineral Clinic, Detroit, MI
Background/Purpose: Denosumab (DMAb) is approved for the treatment of postmenopausal women with osteoporosis at increased risk for fracture. In the pivotal 3-year FREEDOM trial comparing…
Abstract Number: 348 • 2015 ACR/ARHP Annual Meeting
Incidence Rate of Potential Osteonecrosis of the Jaw Among Women with Postmenopausal Osteoporosis Treated with Prolia or Bisphosphonates
Fei Xue¹, Rachel B Wagman¹, Susan Yue¹, Shawna Smith¹, Tarun Arora², Jeffrey R. Curtis², Vera Ehrenstein³, Henrik T Sørensen³, Grethe Tell⁴, Helle Kieler⁵, Florence T Wang⁶, David D Dore⁶ and J Michael Sprafka¹, ¹Amgen Inc., Thousand Oaks, CA, ²University of Alabama at Birmingham, Birmingham, AL, ³Aarhus University Hospital, Aarhus, Denmark, ⁴University of Bergen, Bergen, Norway, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Optum, Waltham, MA
Background/Purpose: Although a higher risk of osteonecrosis of the jaw (ONJ) has been associated with antiresportive treatment based on spontaneous reports and observational studies, no…
Abstract Number: 349 • 2015 ACR/ARHP Annual Meeting
Comparison Between the American Recommendations and the Japanese Guidelines for Glucocorticoid-Induced Osteoporosis in Japanese Patients with Rheumatoid Arthritis
Takefumi Furuya, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: In 2014, the Japanese Society for Bone and Mineral Research (JSBMR) updated their guidelines for the management and treatment of glucocorticoid-induced osteoporosis (GIO) and…
Abstract Number: 350 • 2015 ACR/ARHP Annual Meeting
Atypical Femur Fracture in Rheumatoid Arthritis Patients Treated with Bisphosphonates: A Nested Case-Control Study
JungHee Koh¹, Ji Hyeon Ju², Min Kyung Chung³, Ji Hun Kim³, Seung Min Jung⁴, Ji Yeon Lee², Jennifer Lee³, Seung-Ki Kwok⁵ and Sung-Hwan Park³, ¹Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) are diagnosed with osteoporosis earlier than and those without RA, and are therefore exposed to Bisphosphonates (BPs) for longer.…
Abstract Number: 351 • 2015 ACR/ARHP Annual Meeting
Trabecular Bone Score Is Severely Affected in Male Patients with Chronic Obstructive Pulmonary Disease
Marta Arévalo Salaet¹, Enrique Casado Burgos¹, M Gallego¹, Luis Del Rio², Marta Larrosa³ and Jordi Gratacos⁴, ¹Hospital Universitari Parc Taulí, Sabadell, Spain, ²CETIR Medical Centre, Terrassa, Spain, ³Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology, Hospital de Sabadell, Sabadell, Spain
Background/Purpose: Patients with chronic obstructive pulmonary disease (COPD) have a high risk of osteoporosis and fractures. In a cohort of male patients with COPD we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].